Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is set to make an impact with its innovative AlloSCOPE platform and robust pipeline of potential therapies for degenerative diseases. Despite the high risk associated with regenerative medicine, the company has shown promising signs of success with its OpRegen program, backed by external validation and support from Roche and Genentech. With a strategic focus on internal development and commercialization, we believe Lineage has the potential for long-term growth and potential for significant clinical wins, making it a solid buy for investors.

Bears say

Lineage Cell Therapeutics is facing challenges with its OpRegen program, as it has yet to yield significant improvements in visual and anatomical measures for patients with age-related macular degeneration (AMD). The company is currently relying on its AlloSCOPE platform and its TAI formulation for scalability, purity, and manufacturing of allogeneic CEnCs, but its dependence on these technologies may not be sustainable in the long run. Furthermore, the company's financial outlook remains uncertain due to the high expenses involved in developing and commercializing cell therapies, and its limited revenue potential from its current pipeline.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.